Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

BioNanoMatrix Receives Grant to Speed Development of Nanoscale Whole-Genome Analyzer

  • BioNanomatrix received a grant from the The National Human Genome Research Institute (NHGRI) to support development of its nanoscale platform for genomic analysis. The two-year, $397,750 SBIR grant was awarded under the NIH BioEngineering Nanotechnology Initiative.

    “The nanochannel array technology we are developing with this funding is designed to permit direct visualization and analysis of multimegabase fragments of DNA at the single-molecule level with high feature resolution, allowing researchers to visualize mutations, haplotypes, epigenetic features, and even DNA-protein binding events,” explains Han Cao, Ph.D., CSO and principal investigator on this grant.

    BioNanomatrix is developing integrated systems that enable nanoscale, single-molecule identification and analysis of the entire genome, delivering single-molecule sensitivity with haplotyping capability in a highly parallel format. The company’s analytic platform, based on this technology provides ultrahigh-resolution analyses of DNA, RNA, and other proteins.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »